1. Scrip

With $3bn Viela Acquisition, Horizon Builds A Pipeline

 
• By Jessica Merrill

Horizon will gain the commercial product Uplizna and three pipeline products for rare diseases, where it can build on its success with Tepezza. Horizon is also interested in Viela's R&D team.

building construction
Horizon is growing with the acquisition of Viela • Source: Shuterstock

Horizon Therapeutics plc is expanding its rare disease portfolio and pipeline with the acquisition of Viela Bio, Inc. for $3.05bn, looking to build on the success Horizon has experienced with the launch of Tepezza (teprotumumab) last year for thyroid eye disease. The acquisition of Viela will substantially bolster Horizon's portfolio, adding one commercial product, Uplizna (inebilizumab) for a rare autoimmune condition, and three pipeline products.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.

Amgen Under Pressure, But Seeing Gains Ahead Of Obesity Readouts

 
• By Mandy Jackson

MariTide could give Amgen a big boost if successful in obesity, but the drug just entered Phase III. Even so, Q1 revenue rose 9% to $8.15bn and more growth is expected in 2025.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.